Scarica l'app Stockscreener
52.74
0.45%
-0.24
Dopo l'orario di chiusura:
52.85
0.11
+0.21%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Precedente Chiudi:
$52.98
Aprire:
$52.82
Volume 24 ore:
2.05M
Relative Volume:
0.65
Capitalizzazione di mercato:
$4.80B
Reddito:
$170.10M
Utile/perdita netta:
$-239.59M
Rapporto P/E:
-18.84
EPS:
-2.8
Flusso di cassa netto:
$-191.20M
1 W Prestazione:
-0.58%
1M Prestazione:
-11.50%
6M Prestazione:
+21.38%
1 anno Prestazione:
+17.12%
Intervallo 1D:
$51.66
$52.99
Intervallo di 1 settimana:
$50.83
$55.15
Portata 52W:
$30.04
$71.13
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Nome
Crispr Therapeutics Ag
Settore
Industria
Telefono
(617) 315-4600
Indirizzo
BAARERSTRASSE 14, ZUG
Confronta CRSP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
52.74 | 4.79B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Aggiornamento | TD Cowen | Sell → Hold |
| 2025-02-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-08-02 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-28 | Ripresa | Guggenheim | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-11 | Downgrade | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Iniziato | Mizuho | Buy |
| 2023-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-04-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2023-03-07 | Iniziato | Robert W. Baird | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-08-09 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-04-21 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-10 | Reiterato | Chardan Capital Markets | Buy |
| 2020-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-10 | Reiterato | Needham | Buy |
| 2020-12-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-07-28 | Reiterato | Needham | Buy |
| 2020-07-14 | Iniziato | SunTrust | Buy |
| 2020-06-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Iniziato | Jefferies | Buy |
| 2019-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-10 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-14 | Iniziato | William Blair | Mkt Perform |
| 2019-01-28 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-22 | Downgrade | Citigroup | Neutral → Sell |
Mostra tutto
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
Rafferty Asset Management LLC Trims Stock Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Orbis Allan Gray Ltd Has $53.19 Million Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Q1 EPS Estimate for CRISPR Therapeutics Raised by Analyst - MarketBeat
CRISPR Therapeutics (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Is CRISPR Therapeutics AG a speculative investment2025 Market Outlook & Weekly Breakout Watchlists - khodrobank.com
Using Bollinger Bands to evaluate CRISPR Therapeutics AGJuly 2025 Decliners & High Conviction Buy Zone Picks - Newser
Historical volatility pattern of CRISPR Therapeutics AG visualizedTrade Entry Report & High Conviction Trade Alerts - Newser
What machine learning models say about CRISPR Therapeutics AGQuarterly Profit Review & Real-Time Buy Signal Alerts - Newser
Should you wait for a breakout in CRISPR Therapeutics AG2025 Retail Activity & High Return Stock Watch Alerts - Newser
Can technical indicators confirm CRISPR Therapeutics AG’s reversalTrade Performance Summary & Free Low Drawdown Momentum Trade Ideas - Newser
Will breakout in CRISPR Therapeutics AG lead to full recoveryJuly 2025 News Drivers & Weekly Chart Analysis and Trade Guides - Newser
Can machine learning forecast CRISPR Therapeutics AG recoveryJuly 2025 EndofMonth & Comprehensive Market Scan Insights - Newser
Visual trend scoring systems applied to CRISPR Therapeutics AGMarket Movement Recap & Low Risk Investment Opportunities - Newser
CRISPR Therapeutics (NASDAQ:CRSP) Stock Rating Upgraded by Zacks Research - MarketBeat
Will CRISPR Therapeutics AG stock recover after recent drop2025 Risk Factors & Expert Approved Trade Ideas - Newser
Is it too late to sell CRISPR Therapeutics AGJuly 2025 Retail & Verified Chart Pattern Trade Signals - Newser
How sentiment analysis helps forecast CRISPR Therapeutics AG2025 Technical Overview & Low Drawdown Trading Strategies - Newser
Forecasting CRISPR Therapeutics AG price range with options data2025 Risk Factors & Accurate Intraday Trade Tips - Newser
Does CRISPR Therapeutics AG have declining or rising EPSWeekly Market Report & Technical Entry and Exit Alerts - khodrobank.com
Can trapped investors hope for a rebound in CRISPR Therapeutics AGWatch List & Verified Momentum Stock Alerts - Newser
Why is CRISPR Therapeutics AG stock going downTrade Analysis Report & Weekly Breakout Stock Alerts - khodrobank.com
Risk Analysis: Is CRISPR Therapeutics AG part of any major indexJuly 2025 Movers & Precise Entry and Exit Recommendations - khodrobank.com
When is the best time to exit CRISPR Therapeutics AGJuly 2025 Update & Safe Entry Point Alerts - Newser
Statistical indicators supporting CRISPR Therapeutics AG’s strength2025 Dividend Review & Community Shared Stock Ideas - Newser
Technical analysis overview for CRISPR Therapeutics AG stockPortfolio Profit Report & Technical Entry and Exit Alerts - Newser
Will CRISPR Therapeutics AG benefit from geopolitical trendsWeekly Trade Summary & Growth Focused Stock Reports - khodrobank.com
Will CRISPR Therapeutics AG benefit from current market trends2025 Technical Patterns & Expert Approved Trade Ideas - khodrobank.com
Crispr Therapeutics: A Winning Lottery Ticket Doesn't Replace Grand Strategy - Seeking Alpha
CRISPR Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
What makes CRISPR Therapeutics AG stock price move sharply2025 Trading Volume Trends & Stock Timing and Entry Methods - Newser
How hedge fund analytics apply to CRISPR Therapeutics AG stockTrade Exit Summary & AI Powered Buy/Sell Recommendations - Newser
Gene Editing Market to Surpass USD 15.46 Billion by 2032, - GlobeNewswire
Gene Editing Market to Surpass USD 15.46 Billion by 2032, Fueled by Breakthroughs in CRISPR Technology and Precision Medicine – SNS Insider - GlobeNewswire Inc.
Is CRISPR Therapeutics AG backed by strong institutional buyingWeekly Investment Report & Free Weekly Chart Analysis and Trade Guides - خودرو بانک
What is the PEG ratio of CRISPR Therapeutics AG2025 Geopolitical Influence & Verified Technical Trade Signals - خودرو بانک
Analyzing recovery setups for CRISPR Therapeutics AG investorsEarnings Summary Report & Free Community Consensus Stock Picks - Newser
How does CRISPR Therapeutics AG perform in inflationary periodsJobs Report & Short-Term High Return Ideas - khodrobank.com
Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Crispr Therapeutics Ag Azioni (CRSP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Treco Douglas A | Director |
Aug 06 '25 |
Buy |
57.03 |
20,000 |
1,140,600 |
22,000 |
| George Simeon | Director |
Jul 16 '25 |
Buy |
52.03 |
989,812 |
51,499,918 |
1,730,179 |
| Patel Naimish | Chief Medical Officer |
May 29 '25 |
Sale |
35.94 |
3,932 |
141,316 |
6,068 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 21 '25 |
Sale |
41.23 |
10,031 |
413,578 |
195,085 |
| Bruno Julianne | Chief Operating Officer |
Mar 21 '25 |
Sale |
41.23 |
1,714 |
70,668 |
10,544 |
| Prasad Raju | Chief Financial Officer |
Mar 21 '25 |
Sale |
41.23 |
2,197 |
90,582 |
16,767 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 21 '25 |
Sale |
41.23 |
3,185 |
131,318 |
81,729 |
| Prasad Raju | Chief Financial Officer |
Mar 17 '25 |
Sale |
41.80 |
3,762 |
157,252 |
12,714 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 11 '25 |
Sale |
42.42 |
9,973 |
423,055 |
180,890 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 12 '25 |
Sale |
43.32 |
4,462 |
193,294 |
185,428 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):